Bavarian Nordic A/S – Interim Report for the period 1 January to ...
In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million ..... combination study with PROSTVAC™ and MDX-010 (CTL4-antibody) in men with
... Financial statement for the period (1 January - 30 June 2009, un-audited)
...
http://www.bavarian-nordic.com/investor/announcements/2009-2...
|
melanoma - Discussion - Skin cancer support group - Inspire
By REDTOYOU; Posted January 30, 2009 at 10:42 am; Report post ... My husband has been on Ipilimubab (MDX-010) since October and is doing well. .... January 2008
orginal Derm. found a small dark spot on upper arm and ...
http://www.inspire.com/groups/skin-cancer/discussion/melanom...
|
Jeffrey S. Weber, MD, PhD - H. Lee Moffitt Cancer Center ...
Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). ..... Project Dates: January 1, 2009 to December 31, 2009
...
http://www.moffitt.org/Site.aspx?spid=8FE18FA088C4410BA9C8C8...
|
Anticancer Antibodies: Unconjugated Antibodies
Edrecolomab (Panorex), January 1995†, GlaxoSmithKline, London, England ... MDX- 010, Medarex, Humanized anti-HER-2 monoclonal antibody; ...... All material on
this website is protected by copyright, Copyright © 1994-2009 by Medscape. ...
http://www.medscape.com/viewarticle/452193_5...
|
Jeffrey S. Weber, MD, PhD - H. Lee Moffitt Cancer Center ...
2009 Oct;30(9):1751-1753. Pubmedid: 19474123. Pubmed ID: 19474123 ... Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (
MDX-010). ..... Project Dates: January 1, 2009 to December 31, 2009 ...
http://www.moffitt.org/Site.aspx?spid=8FE18FA088C4410BA9C8C8...
|
Bristol-Myers Squibb Company to Cut Jobs, Close Plants to Save ...
6 Dec 2007 ... the substantial majority of positions will be eliminated in 2008 and 2009. ... stockholders of record at the close of business on January 4, 2008. ... and
ipilimumab (MDX-010), a potential new immunotherapy paradigm; ...
http://www.biospace.com/news_story.aspx?NewsEntityId=79605...
|
January 8, 2008
March 31, 2009 from FY07 after preliminary data from Phase III Study 301 showed the ... Ipilimumab (MDX-010) misses the primary endpoint in the Phase II 008 ...
http://www.biocentury.com/bcApp/BioCenturyCommon/CustomerSer...
|
Article : GEN's Annual Wall Street Roundup Genetic Engineering ...
1 Feb 2007 ... The company received approval in January 2006 for Ranexa, .... (REGN)) as early as 2009 could be a major threat to Genentech's Avastin franchise. ... Remodulin
for PAH, MDX-010 for metastatic melanoma, AGI-1067 for ...
http://www.genengnews.com/articles/chitem.aspx?aid=1989&chid...
|
Biennial Report on the
development supplements and workshops will be available through FY 2009. ...... MDX-010 (Human Anti-CTLA4 MoAb). IL-12 + IL-2. MEDI-522. LMB-2 Immunotoxin
...... Diagnostic Criteria to be held at NIH on January 26, 2007). ...
http://rarediseases.info.nih.gov/files/BienniaReportRareDise...
|
